Skip to content
Triangle logo TriangleGet started
← Non-Small Cell Lung Cancer

HEALTH PROFESSIONAL · SOURCE READING

Other systemic consolidation therapies

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage IIIA NSCLC / Treatment Options for Unresectable Stage IIIA NSCLC / Chemoradiation therapy / Consolidation therapy following concurrent chemoradiation

The addition of induction chemotherapy before concurrent chemotherapy and radiation therapy has not been shown to improve survival.[49][Level of evidence A1]

Source links and citations

Randomized trials of other consolidation systemic therapies, including docetaxel,[50] gefitinib,[51] and tecemotide (MUC1 antigen-specific immunotherapy) [52] have not shown an improvement in OS.[Level of evidence A1]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice